Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 293

1.

Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.

Howard JF Jr, Nowak RJ, Wolfe GI, Freimer ML, Vu TH, Hinton JL, Benatar M, Duda PW, MacDougall JE, Farzaneh-Far R, Kaminski HJ; and the Zilucoplan MG Study Group, Barohn R, Dimachkie M, Pasnoor M, Farmakidis C, Liu T, Colgan S, Benatar MG, Bertorini T, Pillai R, Henegar R, Bromberg M, Gibson S, Janecki T, Freimer M, Elsheikh B, Matisak P, Genge A, Guidon A, David W, Habib AA, Mathew V, Mozaffar T, Hinton JL, Hewitt W, Barnett D, Sullivan P, Ho D, Howard JF Jr, Traub RE, Chopra M, Kaminski HJ, Aly R, Bayat E, Abu-Rub M, Khan S, Lange D, Holzberg S, Khatri B, Lindman E, Olapo T, Sershon LM, Lisak RP, Bernitsas E, Jia K, Malik R, Lewis-Collins TD, Nicolle M, Nowak RJ, Sharma A, Roy B, Nye J, Pulley M, Berger A, Shabbir Y, Sachdev A, Patterson K, Siddiqi Z, Sivak M, Bratton J, Small G, Kohli A, Fetter M, Vu T, Lam L, Harvey B, Wolfe GI, Silvestri N, Patrick K, Zakalik K, Duda PW, MacDougall J, Farzaneh-Far R, Pontius A, Hoarty M.

JAMA Neurol. 2020 Feb 17. doi: 10.1001/jamaneurol.2019.5125. [Epub ahead of print]

PMID:
32065623
2.

Cataclysmically disseminating neurologic presentation in an immunosuppressed lupus patient: From the National Multiple Sclerosis Society Case Conference Proceedings.

Perrone CM, Lisak RP, Meltzer EI, Sguigna P, Tizazu E, Jacobs D, Melamed E, Lucas A, Freeman L, Pardo G, Goodman A, Fox EJ, Costello K, Parsons MS, Zamvil SS, Frohman EM, Frohman TC.

Neurol Neuroimmunol Neuroinflamm. 2019 Jun 13;6(4):e582. doi: 10.1212/NXI.0000000000000582. eCollection 2019 Jul. No abstract available.

3.

Human retrovirus pHEV-W envelope protein and the pathogenesis of multiple sclerosis.

Lisak RP.

Proc Natl Acad Sci U S A. 2019 Jul 23;116(30):14791-14793. doi: 10.1073/pnas.1909786116. Epub 2019 Jul 9. No abstract available.

4.

Exosome-enriched fractions from MS B cells induce oligodendrocyte death.

Benjamins JA, Nedelkoska L, Touil H, Stemmer PM, Carruthers NJ, Jena BP, Naik AR, Bar-Or A, Lisak RP.

Neurol Neuroimmunol Neuroinflamm. 2019 Apr 9;6(3):e550. doi: 10.1212/NXI.0000000000000550. eCollection 2019 May.

5.

Cerebellar syndrome in a man treated with natalizumab: From the National Multiple Sclerosis Society Case Conference Proceedings.

Lapides DA, Batchala PP, Donahue JH, Lisak RP, Meltzer EI, Narayan RN, Nath A, Frohman TC, Costello K, Goldman MD, Zamvil SS, Frohman EM.

Neurol Neuroimmunol Neuroinflamm. 2019 Mar 7;6(3):e546. doi: 10.1212/NXI.0000000000000546. eCollection 2019 May. No abstract available.

6.

Serum Creatine Kinase in Patients with Neuromyelitis Optica Spectrum Disorder.

Shouman K, Prieto PG, Stino AM, Lisak RP.

J Neuroimmunol. 2019 May 15;330:87-89. doi: 10.1016/j.jneuroim.2018.12.008. Epub 2018 Dec 23.

PMID:
30851543
7.

A young man in "double-trouble": Hallucinations and cranial nerve palsies: From the National Multiple Sclerosis Society Case Conference Proceedings.

Bradshaw MJ, Lisak RP, Meltzer E, Melamed E, Lucas A, Freeman L, Frohman TC, Costello K, Balcer L, Galetta S, Chitnis T, Zamvil SS, Frohman EM.

Neurol Neuroimmunol Neuroinflamm. 2018 Dec 19;6(1):e526. doi: 10.1212/NXI.0000000000000526. eCollection 2019 Jan. No abstract available.

8.

A young man with numbness in arms and legs: From the National Multiple Sclerosis Society Case Conference Proceedings.

Romeo AR, Lisak RP, Meltzer E, Fox EJ, Melamed E, Lucas A, Freeman L, Frohman TC, Costello K, Zamvil SS, Frohman EM, Gelfand JM.

Neurol Neuroimmunol Neuroinflamm. 2018 Oct 23;5(6):e509. doi: 10.1212/NXI.0000000000000509. eCollection 2018 Nov. No abstract available.

9.

Where there is inflammation, treatment may reduce disability progression - Commentary.

Rube J, Lisak RP.

Mult Scler. 2018 Oct 8:1352458518799639. doi: 10.1177/1352458518799639. [Epub ahead of print] No abstract available.

PMID:
30295573
10.

New onset myasthenia gravis in a patient with non small cell lung cancer treated with lorlatinib a novel anti-cancer agent.

Desai A, Sriwastava S, Gadgeel SM, Lisak RP.

J Neurol Sci. 2018 Sep 15;392:100-101. doi: 10.1016/j.jns.2018.06.024. Epub 2018 Jul 2. No abstract available.

PMID:
30031992
11.

Nature and Action of Antibodies in Myasthenia Gravis.

Ruff RL, Lisak RP.

Neurol Clin. 2018 May;36(2):275-291. doi: 10.1016/j.ncl.2018.01.001. Review.

PMID:
29655450
12.

Obituary-Omar Khan, MD, Professor and Chair of Neurology and Neurologist-in-Chief of the Detroit Medical Center.

Lisak RP, Dhib-Jalbut S.

Mult Scler. 2016 Oct;22(11):1385. doi: 10.1177/1352458516669864. No abstract available.

PMID:
29130780
13.

Melanocortin receptor subtypes are expressed on cells in the oligodendroglial lineage and signal ACTH protection.

Benjamins JA, Nedelkoska L, Lisak RP.

J Neurosci Res. 2018 Mar;96(3):427-435. doi: 10.1002/jnr.24141. Epub 2017 Sep 6.

PMID:
28877366
14.

Melanocortins, Melanocortin Receptors and Multiple Sclerosis.

Lisak RP, Benjamins JA.

Brain Sci. 2017 Aug 14;7(8). pii: E104. doi: 10.3390/brainsci7080104. Review.

15.

B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro.

Lisak RP, Nedelkoska L, Benjamins JA, Schalk D, Bealmear B, Touil H, Li R, Muirhead G, Bar-Or A.

J Neuroimmunol. 2017 Aug 15;309:88-99. doi: 10.1016/j.jneuroim.2017.05.004. Epub 2017 May 17.

PMID:
28601295
16.

Expanding the Range of Diagnosable Autoimmune Encephalopathies and Encephalomyelopathies.

Lisak RP.

JAMA Neurol. 2016 Nov 1;73(11):1279-1280. doi: 10.1001/jamaneurol.2016.2970. No abstract available.

PMID:
27617980
17.

Schwann cell differentiation inhibits interferon-gamma induction of expression of major histocompatibility complex class II and intercellular adhesion molecule-1.

Lisak RP, Bealmear B, Benjamins JA.

J Neuroimmunol. 2016 Jun 15;295-296:93-9. doi: 10.1016/j.jneuroim.2016.03.013. Epub 2016 Apr 7.

PMID:
27235355
18.

The melanocortin ACTH 1-39 promotes protection of oligodendrocytes by astroglia.

Lisak RP, Nedelkoska L, Benjamins JA.

J Neurol Sci. 2016 Mar 15;362:21-6. doi: 10.1016/j.jns.2016.01.009. Epub 2016 Jan 7.

PMID:
26944112
19.

Melanocortin receptor agonist ACTH 1-39 protects rat forebrain neurons from apoptotic, excitotoxic and inflammation-related damage.

Lisak RP, Nedelkoska L, Bealmear B, Benjamins JA.

Exp Neurol. 2015 Nov;273:161-7. doi: 10.1016/j.expneurol.2015.08.012. Epub 2015 Aug 20.

PMID:
26300474
20.

Emerging role of IL-16 in cytokine-mediated regulation of multiple sclerosis.

Skundric DS, Cruikshank WW, Montgomery PC, Lisak RP, Tse HY.

Cytokine. 2015 Oct;75(2):234-48. doi: 10.1016/j.cyto.2015.01.005. Epub 2015 Feb 18.

PMID:
25703787
21.

New insights into the genetics of autoimmune myasthenia gravis: an evolving story.

Lisak RP, Barcellos L.

JAMA Neurol. 2015 Apr;72(4):386-7. doi: 10.1001/jamaneurol.2014.4493. No abstract available.

PMID:
25643244
22.

Neuromuscular junction as Achilles' heel: yet another autoantibody?

Lisak RP, Zhang B, Shen C, Mei L.

Neurology. 2015 Jan 13;84(2):214-5. doi: 10.1212/WNL.0000000000001140. No abstract available.

PMID:
25583827
23.

Adrenocorticotropin hormone 1-39 promotes proliferation and differentiation of oligodendroglial progenitor cells and protects from excitotoxic and inflammation-related damage.

Benjamins JA, Nedelkoska L, Lisak RP.

J Neurosci Res. 2014 Oct;92(10):1243-51. doi: 10.1002/jnr.23416. Epub 2014 Jun 11.

PMID:
24916309
24.

Paraneoplastic neuromyelitis optica spectrum disorder associated with metastatic carcinoid expressing aquaporin-4.

Figueroa M, Guo Y, Tselis A, Pittock SJ, Lennon VA, Lucchinetti CF, Lisak RP.

JAMA Neurol. 2014 Apr;71(4):495-8. doi: 10.1001/jamaneurol.2013.6331.

25.

Autoantibodies to agrin in myasthenia gravis patients.

Zhang B, Shen C, Bealmear B, Ragheb S, Xiong WC, Lewis RA, Lisak RP, Mei L.

PLoS One. 2014 Mar 14;9(3):e91816. doi: 10.1371/journal.pone.0091816. eCollection 2014.

26.

Effects of dextromethorphan on glial cell function: proliferation, maturation, and protection from cytotoxic molecules.

Lisak RP, Nedelkoska L, Benjamins JA.

Glia. 2014 May;62(5):751-62. doi: 10.1002/glia.22639. Epub 2014 Feb 13.

PMID:
24526455
27.

Globalization of neurology: development of the WFN Journal of the Neurological Sciences.

Lisak RP.

Neurology. 2014 Jan 14;82(2):172-3. doi: 10.1212/WNL.0000000000000010. No abstract available.

PMID:
24419977
28.

The American Academy of Neurology's top five Choosing Wisely recommendations.

Mattson DH, Lisak RP, Jones DE, Corboy JR, Larson R, Gronseth G, Getchius TS, Langer-Gould A, Langer-Gould AM, Gronseth GS, Larson R, Getchius TS.

Neurology. 2013 Sep 10;81(11):1022-3. doi: 10.1212/WNL.0b013e3182a69c98. No abstract available.

PMID:
24019388
29.

ACTH protects mature oligodendroglia from excitotoxic and inflammation-related damage in vitro.

Benjamins JA, Nedelkoska L, Bealmear B, Lisak RP.

Glia. 2013 Aug;61(8):1206-17. doi: 10.1002/glia.22504. Epub 2013 Jul 5.

PMID:
23832579
30.

Complexity of trophic factor signaling in experimental autoimmune encephalomyelitis: differential expression of neurotrophic and gliotrophic factors.

Song F, Bandara M, Deol H, Loeb JA, Benjamins J, Lisak RP.

J Neuroimmunol. 2013 Sep 15;262(1-2):11-8. doi: 10.1016/j.jneuroim.2013.05.012. Epub 2013 Jun 12.

31.

Farewell editorial.

Lisak RP.

J Neurol Sci. 2013 Jul 15;330(1-2):1. doi: 10.1016/j.jns.2013.05.007. Epub 2013 May 17. No abstract available.

PMID:
23684669
32.

Ectopic germinal centers, BAFF and anti-B-cell therapy in myasthenia gravis.

Berrih-Aknin S, Ragheb S, Le Panse R, Lisak RP.

Autoimmun Rev. 2013 Jul;12(9):885-93. doi: 10.1016/j.autrev.2013.03.011. Epub 2013 Mar 26.

PMID:
23537509
33.

The role of B cell-activating factor in autoimmune myasthenia gravis.

Lisak RP, Ragheb S.

Ann N Y Acad Sci. 2012 Dec;1274:60-7. doi: 10.1111/j.1749-6632.2012.06842.x.

PMID:
23252898
34.

Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis.

Arnason BG, Berkovich R, Catania A, Lisak RP, Zaidi M.

Mult Scler. 2013 Feb;19(2):130-6. doi: 10.1177/1352458512458844. Epub 2012 Oct 3. Review.

35.

Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro.

Lisak RP, Benjamins JA, Nedelkoska L, Barger JL, Ragheb S, Fan B, Ouamara N, Johnson TA, Rajasekharan S, Bar-Or A.

J Neuroimmunol. 2012 May 15;246(1-2):85-95. doi: 10.1016/j.jneuroim.2012.02.015. Epub 2012 Mar 28.

PMID:
22458983
36.

Myasthenia gravis.

Aarli JA, Gilhus NE, Lisak RP, Mantegazza R, Suzuki S.

Autoimmune Dis. 2011;2011:697575. doi: 10.4061/2011/697575. Epub 2012 Jan 24. No abstract available.

37.

B-cell-activating factor and autoimmune myasthenia gravis.

Ragheb S, Lisak RP.

Autoimmune Dis. 2011;2011:939520. doi: 10.4061/2011/939520. Epub 2011 Nov 28.

38.

Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis.

Zhang B, Tzartos JS, Belimezi M, Ragheb S, Bealmear B, Lewis RA, Xiong WC, Lisak RP, Tzartos SJ, Mei L.

Arch Neurol. 2012 Apr;69(4):445-51. doi: 10.1001/archneurol.2011.2393. Epub 2011 Dec 12.

PMID:
22158716
39.

Cytokines regulate neuronal gene expression: differential effects of Th1, Th2 and monocyte/macrophage cytokines.

Lisak RP, Nedelkoska L, Studzinski D, Bealmear B, Xu W, Benjamins JA.

J Neuroimmunol. 2011 Sep 15;238(1-2):19-33. doi: 10.1016/j.jneuroim.2011.06.010. Epub 2011 Jul 30.

PMID:
21803433
40.

Cytokines reduce toxic effects of ethanol on oligodendroglia.

Benjamins JA, Nedelkoska L, Lisak RP, Hannigan JH, Sokol RJ.

Neurochem Res. 2011 Sep;36(9):1677-86. doi: 10.1007/s11064-011-0401-x. Epub 2011 Jan 29.

PMID:
21279438
41.

Myasthenia gravis.

Jani-Acsadi A, Lisak RP.

Curr Treat Options Neurol. 2010 May;12(3):231-43. doi: 10.1007/s11940-010-0070-0.

PMID:
20842584
42.

Approaches to neuroprotective strategies in multiple sclerosis.

Tselis A, Khan OA, Lisak RP.

Expert Opin Pharmacother. 2010 Dec;11(17):2869-78. doi: 10.1517/14656566.2010.508070. Epub 2010 Aug 5. Review.

PMID:
20687779
43.

The immunopathogenesis of Guillain-Barré syndrome.

Ramchandren S, Lisak RP.

Clin Adv Hematol Oncol. 2010 Mar;8(3):203-6. Review. No abstract available.

PMID:
20400936
44.

Insights for practice: where mechanism of action meets patient management.

Lisak RP, Korngold S.

Neurology. 2010 Jan 5;74 Suppl 1:S70-3. doi: 10.1212/WNL.0b013e3181c981c0. No abstract available.

PMID:
20038766
45.

Cytokines decrease expression of interleukin-6 signal transducer and leptin receptor in central nervous system glia.

Rose JJ, Bealmear B, Nedelkoska L, Studzinski D, Lisak RP, Benjamins JA.

J Neurosci Res. 2009 Nov 1;87(14):3098-106. doi: 10.1002/jnr.22135.

PMID:
19479985
46.

Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for molecules associated with metabolism, signaling and regulation in central nervous system mixed glial cell cultures.

Lisak RP, Benjamins JA, Bealmear B, Nedelkoska L, Studzinski D, Retland E, Yao B, Land S.

J Neuroinflammation. 2009 Jan 21;6:4. doi: 10.1186/1742-2094-6-4.

47.

The two articles published in the Journal of Neurological Sciences by Dr. Oka.

Lisak RP.

J Neurol Sci. 2011 Oct 15;309(1-2):e2. doi: 10.1016/j.jns.2008.07.011. Epub 2008 Aug 20. No abstract available.

PMID:
18718606
49.

Neurodegeneration in multiple sclerosis: defining the problem.

Lisak RP.

Neurology. 2007 May 29;68(22 Suppl 3):S5-12; discussion S43-54.

PMID:
17548569
50.

Supplemental Content

Loading ...
Support Center